G8937 HCPCS: Reimbursement & Policy Benchmarks | OpenPayer

Summary & Overview

HCPCS G8937: No ACE or ARB Therapy Documented

HCPCS Level II code G8937 denotes that a clinician did not prescribe ACE inhibitor or ARB therapy and did not document a reason. This code captures a specific medication-prescribing decision point that is relevant to quality measurement, care coordination, and medication safety programs nationally. Use of G8937 affects clinical documentation workflows and may factor into payer quality reporting and claims review processes.

Key payers considered in this context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of what the code represents, the clinical circumstances in which it is used, and the typical ambulatory or outpatient setting for reporting. The publication outlines benchmarks and reporting implications where available, summarizes how payers may view nondocumentation of ACE/ARB prescribing, and highlights policy and documentation considerations that influence coding and claims processing.

The content provides a concise reference for coding staff, compliance officers, and clinicians seeking to understand the purpose and reporting context of G8937, without offering clinical recommendations. Data not available in the input will be noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG8937HCPCS Level IImedication managementACE inhibitorARBquality reportingambulatory careclinical documentation

Billing Code Overview

HCPCS Level II code G8937 indicates that the clinician did not prescribe angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy, with no reason documented. The service type is medication management / prescribing decision reflecting documentation about absence of ACE inhibitor or ARB therapy. The typical site of service is ambulatory or outpatient clinical encounters, where prescribing decisions and medication reconciliation are recorded.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A patient with a history of hypertension and/or heart failure is seen in an outpatient primary care or cardiology clinic for medication reconciliation and chronic disease management. During the visit the clinician documents that angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy was considered but not prescribed, and no reason for withholding ACE/ARB therapy is recorded. Typical workflow: history and medication review, assessment of blood pressure and renal function (basic metabolic panel), evaluation for contraindications (e.g., pregnancy, history of angioedema), discussion with patient, and documentation of treatment decisions. The billing code G8937 is used to indicate that ACE/ARB therapy was not prescribed and that the reason was not given in the chart. Typical sites of service include outpatient clinic, ambulatory care center, and cardiology practice. Typical patient scenario: a middle-aged patient with systolic hypertension and prior myocardial infarction presents for routine follow-up; the clinician reviews current medications, decides against initiating ACE/ARB therapy during the visit, and documents the decision without specifying the clinical rationale.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when additional work or time beyond the typical visit is documented (e.g., complex medication reconciliation or counseling).

HCPCS G9159: Spoken Language Comprehension Functional Limitation

HCPCS-G9191-DOCUMENTATION-BETA-BLOCKER-DECLINE-OR-REASON

HCPCS G9191: Documentation of Patient Reason(s) for Not Prescribing Beta-Blocker Therapy

HCPCS-G8696-ANTITHROMBOTIC-THERAPY-PRESCRIBED-AT-DISCHARGE

HCPCS G8696: Antithrombotic Therapy Prescribed at Discharge

HCPCS-G0472-HEPATITIS-C-ANTIBODY-SCREENING-HIGH-RISK

HCPCS G0472: Hepatitis C Antibody Screening for High-Risk Individuals

HCPCS-G0533-BUPRENORPHINE-WEEKLY-MEDICATION-ASSISTED-TREATMENT-BUNDLE

HCPCS G0533: Weekly Injectable Buprenorphine Medication Assisted Treatment Bundle

HCPCS-G4036-URGENT-CARE-MIPS-SPECIALTY-SET

HCPCS G4036: Urgent Care MIPS Specialty Set

HCPCS-G8957-PATIENT-NOT-ON-MAINTENANCE-HEMODIALYSIS-OUTPATIENT-DIALYSIS-FACILITY

HCPCS G8957: Patient Not Receiving Maintenance Hemodialysis in Outpatient Dialysis Facility

HCPCS-G8430-MEDICAL-REASON-FOR-NOT-DOCUMENTING-MEDICATION-LIST

HCPCS G8430: Medical Reason for Not Documenting Medication List

HCPCS-G0090-HOME-INFUSION-INITIAL-VISIT-IV-CHEMOTHERAPY

HCPCS G0090: Initial Home Visit for IV Chemotherapy or Complex Infusion

HCPCS-G0452-MOLECULAR-PATHOLOGY-PHYSICIAN-INTERPRETATION-REPORT

HCPCS G0452: Molecular Pathology Physician Interpretation and Report

Showing 1–10 of 1996

Taxonomy Code	Specialty	Notes
`207Q00000X`	Family Medicine	Primary care clinicians who manage hypertension and medication decisions.
`208D00000X`	Internal Medicine	Internists commonly manage chronic cardiovascular and renal conditions and ACE/ARB decisions.
`207RC0000X`	Cardiology	Cardiologists managing heart failure, post-MI therapy decisions.
`363L00000X`	Nurse Practitioner	Advanced practice providers who commonly perform medication management in clinics.
`363A00000X`	Physician Assistant	PAs who perform follow-up visits and document medication decisions.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`I10`	Essential (primary) hypertension	Most common indication for considering ACE inhibitor or ARB therapy; relevant to documentation when therapy is not prescribed.
`I50.9`	Heart failure, unspecified	ACE/ARB therapy is guideline-directed in many forms of systolic heart failure; omission without reason is documented with `G8937`.
`I25.10`	Atherosclerotic heart disease of native coronary artery without angina pectoris	Post-myocardial infarction or ischemic heart disease patients often are candidates for ACE/ARB therapy; decision not to prescribe is relevant.
`E11.9`	Type 2 diabetes mellitus without complications	Diabetes increases cardiovascular and renal risk; ACE/ARB therapy is commonly considered for renal protection and BP control.
`N18.9`	Chronic kidney disease, unspecified	Renal dysfunction influences ACE/ARB prescribing decisions; labs and rationale are clinically relevant.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common E/M level used for follow-up visits where medication decisions such as not prescribing ACE/ARB are documented.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used when visit complexity and decision-making are higher, often accompanying detailed medication reconciliation and chronic disease management.
`81002`	Urinalysis, non-automated, without microscopy	Performed frequently before initiating ACE/ARB to assess baseline renal status; may be ordered or reviewed during the visit.
`80048`	Basic metabolic panel (calcium, total)	Includes serum creatinine and potassium assessment relevant to ACE/ARB safety; often reviewed prior to initiation.
`93000`	Electrocardiogram, routine ECG with at least 12 leads; interpretation and report	Sometimes performed in cardiovascular evaluation visits that address medication management decisions.

OpenPayer